2. Academic Validation
  3. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

  • J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. doi: 10.1124/jpet.121.000743.
Patricia Schroeder 1,  Keertik Fulzele 1,  Sanjeev Forsyth 1,  Maria D Ribadeneira 1,  Sylvie Guichard 1,  Erik Wilker 1,  C Gary Marshall 1,  Adam Drake 1,  Rose Fessler 1,  Diamantis G Konstantinidis 1,  Katie G Seu 1,  Theodosia A Kalfa 2
Affiliations

Affiliations

  • 1 Forma Therapeutics, Watertown, Massachusetts (P.S., K.F., S.F., M.D.R., S.G.); Tango Therapeutics, Cambridge, Massachusetts (E.W.); Repare Therapeutics, Cambridge, Massachusetts (C.G.M.); Ichnos Sciences, Epalinges, Switzerland (A.D.); Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (R.F., D.G.K., K.G.S., T.A.K.); and Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio (T.A.K.).
  • 2 Forma Therapeutics, Watertown, Massachusetts (P.S., K.F., S.F., M.D.R., S.G.); Tango Therapeutics, Cambridge, Massachusetts (E.W.); Repare Therapeutics, Cambridge, Massachusetts (C.G.M.); Ichnos Sciences, Epalinges, Switzerland (A.D.); Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (R.F., D.G.K., K.G.S., T.A.K.); and Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio (T.A.K.) Theodosia.Kalfa@cchmc.org.
PMID: 35031585 DOI: 10.1124/jpet.121.000743
Abstract

Etavopivat is an investigational, oral, small molecule activator of erythrocyte Pyruvate Kinase (PKR) in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. PKR activation is proposed to ameliorate the sickling of SCD red blood cells (RBCs) through multiple mechanisms, including reduction of 2,3-diphosphoglycerate (2,3-DPG), which consequently increases hemoglobin (Hb)-oxygen affinity; increased binding of oxygen reduces sickle hemoglobin polymerization and sickling. In addition, PKR activation increases adenosine triphosphate (ATP) produced via glycolytic flux, which helps preserve membrane integrity and RBC deformability. We evaluated the pharmacodynamic response to etavopivat in nonhuman primates (NHPs) and in healthy human subjects and evaluated the effects in RBCs from patients with SCD after ex vivo treatment with etavopivat. A single dose of etavopivat decreased 2,3-DPG in NHPs and healthy subjects. Hb-oxygen affinity was significantly increased in healthy subjects after 24 hours. After daily dosing of etavopivat over 5 consecutive days in NHPs, ATP was increased by 38% from baseline. Etavopivat increased Hb-oxygen affinity and reduced sickling in RBCs collected from patients with SCD with either homozygous hemoglobin S or hemoglobin S and C disease. Collectively, these results demonstrate the ability of etavopivat to decrease 2,3-DPG and increase ATP, resulting in increased Hb-oxygen affinity and improved sickle RBC function. Etavopivat is currently being evaluated in clinical trials for the treatment of SCD. SIGNIFICANCE STATEMENT: Etavopivat, a small molecule activator of the glycolytic Enzyme erythrocyte Pyruvate Kinase, decreased 2,3-diphosphoglycerate in red blood cells (RBCs) from nonhuman primates and healthy subjects and significantly increased hemoglobin (Hb)-oxygen affinity in healthy subjects. Using ex vivo RBCs from donors with sickle cell disease (SCD) (homozygous hemoglobin S or hemoglobin S and C genotype), etavopivat increased Hb-oxygen affinity and reduced sickling under deoxygenation. Etavopivat shows promise as a treatment for SCD that could potentially reduce vaso-occlusion and improve anemia.

Figures
Products